摘要
目的对比在急性心肌梗死溶栓治疗中应用尿激酶、瑞替普酶的效果和价值。方法回顾性选取2020年3月—2021年8月巴中市中心医院收治的84例急性心肌梗死且接受溶栓治疗患者,随机分组。对照组43例给予尿激酶治疗,观察组41例予以瑞替普酶治疗,观察两组临床疗效、血管再通率和治疗不同时段神经功能缺损程度及日常生活活动能力改善情况、心脏不良事件及药物不良反应发生率。结果观察组临床总有效率和血管再通率分别为95.12%、97.56%,高于对照组的79.06%、81.39%,差异有统计学意义(χ^(2)=4.752、4.168,P<0.05)。与对照组相比,观察组患者治疗后不同时段NIHSS评分较低,ADL评分较高,差异有统计学意义(P<0.05)。观察组心脏不良事件发生率为4.87%,药物不良反应发生率为7.31%,低于对照组的23.25%、25.58%,差异有统计学意义(χ^(2)=5.788、5.040,P<0.05)。结论与尿激酶相比,在急性心肌梗死患者的溶栓治疗中应用瑞替普酶效果显著且应用价值较高。
Objective To compare the effect and value of urokinase and Reteplase in the thrombolytic treatment of acute myocardial infarction.Methods Retrospctire selection 84 patients with acute myocardial infarction who received thrombolytic therapy in Bazhong Central Hospital from March 2020 to August 2021 and were randomly grouped.43 patients in the control group were treated with urokinase and 41 patients in the observation group were treated with Reteplase,and the clinical efficacy,revascularization rate,improvement in the degree of neurological deficits and activities of daily living in the patients during different periods of treatment,incidence of adverse cardiac events and adverse drug reactions were observed between the two groups.Results The total clinical effective rate and revascularization rate in the observation group were 95.12%and 97.56%,which was lower than 79.06%and 81.39%in the control group,and the difference was statistically significant(χ^(2)=4.752,4.168,P<0.05).Compared with the control group,patients of observation group had lower NIHSS scores and higher ADL scores at different time after treatment,and the difference was statistically significant(P<0.05).The incidence of adverse cardiac events in the observation group was 4.87%and the incidence of adverse drug reactions was 7.31%,which was lower than 23.25%and 25.58%of the control group,and the difference was statistically significant(χ^(2)=5.788,5.040,P<0.05).Conclusion Compared with urokinase,the application of Reteplase in the thrombolytic treatment of patients with acute myocardial infarction is effective and of high value.
作者
刘芙蓉
LIU Furong(Department of Cardiology,Bazhong Central Hospital,Bazhong,Sichuan Province,636000 China)
出处
《世界复合医学》
2022年第11期160-163,181,共5页
World Journal of Complex Medicine
基金
四川省科学计划项目(2018JY0308)。
关键词
急性心肌梗死
溶栓治疗
尿激酶
瑞替普酶
血管再通率
Acute myocardial infarction
Thrombolytic therapy
Urokinase
Reteplase
Revascularization rate
